Publication Cover
Inhalation Toxicology
International Forum for Respiratory Research
Volume 32, 2020 - Issue 7
122
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

Exploration of therapeutic role of montelukast and dexamethasone combination against paraquat induced inhalational toxicity

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 299-310 | Received 01 Jan 2020, Accepted 14 Jun 2020, Published online: 28 Jun 2020
 

Abstract

Objectives

To explore the therapeutic role of a single dose combination of montelukast (MON) and dexamethasone (DXM) through intra-peritoneal route against paraquat (PQ)-intoxicated experimental Wistar rats.

Methods

In vivo the survival rate was investigated following the administration of both MON and DXM in PQ exposed rats. Lungs parameters including enhanced pause (Penh), tidal volume (TV) and breath per minute (BPM) were determined using the whole body plethysmograph (WBP). Further chest imaging and histopathological studies were conducted to evaluate the lungs injury. In vivo the antioxidant activity was carried out by determining the levels of catalase (SOD), superoxide dismutase (CAT) and glutathione peroxidase (GSH-Px). Lungs tissue concentration of different proinflammatory cytokines like IL-1β, IL-6, TGF-β1 and TNF-α was also determined. Finally, expression of NF-kB and p-NF-kB was investigated by western blot.

Results

Results of survival rate and levels of lungs parameters indicated therapeutic potential of combination treatment of MON and DXM. Protective activity on lungs was reflected in chest imaging and histopathological investigations. Moreover, combination treatment exhibited significant increased levels of all anti-oxidant parameters. Significant decrease in the levels of IL-1β; IL-6; TGF-β1 and TNF-α was also observed with the combination treatment of MON and DXM. Evidence of significant down regulation of NF-kB and phospho-NF-kB was also found with the combination treatment of MON and DXM.

Conclusions

Given the advantage of therapeutic synergism activity of MON and DXM, it may be used in the prophylaxis of PQ-intoxication following clinical trials.

Acknowledgements

The authors sincerely thank the Director, Defence Research Laboratory (DRL), Tezpur, Assam, India, for providing necessary laboratory facilities to execute this research work. The first author is grateful to Defence Research Development Organization (DRDO), Ministry of Defence, Government of India for the provision of a research fellowship (Letter no. DRL/1206/TC/04, dated 1 December 2014). The authors also convey their sincere gratitude to IFTM University, Moradabad for necessary support to carry out doctoral research work and providing necessary administrative support. The authors convey their sincere gratitude to Dr. Lakshmi Narayan Mandal and Dr. Susanta Kumar Bardhan for their diligent proofreading of this article.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.